Overview - The report provides a comprehensive analysis of the synthetic biology industry in China, covering its development status, market trends, and competitive landscape from 2025 to 2031 [1][3]. Industry Definition and Structure - Synthetic biology is defined and categorized, with a detailed breakdown of the industry chain structure and ecosystem [3][4]. - The report includes a regional heat map illustrating the distribution of synthetic biology activities across different areas [3]. Global Development and Trends - The global synthetic biology industry has experienced significant growth, with a focus on policy and technology analysis, including patent applications and key players [4][5]. - Market size and structure are analyzed, highlighting the growth potential in various segments [4][5]. Chinese Market Analysis - The report details the current state of the synthetic biology industry in China, including its historical development and unique characteristics [5][6]. - It discusses the commercial models prevalent in the industry and identifies representative companies [5][6]. Investment and Financing - An analysis of investment trends in the synthetic biology sector reveals significant funding activities and the distribution of investment across different fields [6][7]. - The report summarizes key financing events and the overall investment landscape [6][7]. Competitive Landscape - The competitive dynamics of the synthetic biology industry in China are examined, including the types and numbers of competitors [7][8]. - The report assesses the competitive positioning of leading companies and their strategies for global expansion [7][8]. Technological Development - The report highlights the current state of technology standards in synthetic biology, including ongoing research and development efforts [8][9]. - Key technologies such as gene sequencing and editing are analyzed for their impact on the industry [8][9]. Future Outlook - The report predicts future growth points for the synthetic biology industry, driven by downstream application markets and supportive national policies [9][10]. - It outlines potential investment opportunities and strategic recommendations for stakeholders in the industry [10][11].

Core Viewpoint - The article discusses the development of humanized "4D" collagen protein based on natural collagen, aiming to address the immunogenicity and pathogenic risks associated with traditional animal-derived collagen [1]. Group 1: Research and Development - The research team led by Professor Li Shuang from South China University of Technology focuses on biomimetic "honeycomb" porous structures for molecular construction, optimizing collagen triple helix sequences through gene editing [1]. - The team combines computer simulation design with cross-scale self-assembly templates to achieve a synergistic optimization of high specific surface area, strong mechanical strength, and biological activity [1]. - Techniques such as transmission electron microscopy are utilized to analyze the hierarchical structure, and in vitro cell experiments validate the biocompatibility and regenerative efficacy of the developed materials [1]. Group 2: Industry Applications - The innovative collagen material is expected to provide new biological materials for regenerative medicine, promoting upgrades in industries such as medical aesthetics and bone repair [1]. - Professor Li Shuang will present a talk titled "Molecular Design of Humanized '4D' Collagen Protein" at the SynBioCon 2025 conference, which focuses on synthetic biology and green biological manufacturing [1][14]. Group 3: Conference Details - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, as well as advancements in green chemistry, new materials, future food, and agriculture [14]. - The conference will feature various activities, including a youth forum on biological manufacturing, high-level discussions on the industry, and a closed-door seminar on the "2025 Artificial Intelligence Empowering Biological Manufacturing Industry Innovation Development Blue Book" [14][15].

Core Viewpoint - The Ministry of Agriculture and Rural Affairs, along with ten other departments, has introduced a plan to promote agricultural product consumption, focusing on optimizing supply, innovating circulation, and activating the market through 23 specific measures to adapt to new consumer trends and preferences [1]. Group 1: Nutritional and Health Consumption - There is a shift in consumer demand from "sufficient food" to "nutritious and healthy food," prompting the Ministry to advocate for increased consumption of soybeans and milk to help consumers form a scientific dietary structure [1][2]. - Current data indicates that the average per capita milk consumption in China is 40.5 kg, significantly below the recommended dietary intake of 110-183 kg, and lower than the 80-90 kg levels in Japan and South Korea [2]. - Soybean and soybean product consumption is also below the recommended levels by 59%, indicating substantial growth potential in these areas [2]. Group 2: Public Health and Nutrition Education - The Ministry plans to enhance public services related to nutrition and health by developing and promoting healthy dietary plans, particularly targeting student groups to optimize nutrition in school meals [3]. - There will be a focus on promoting healthy eating habits through campaigns that encourage reduced oil intake, increased consumption of soy and milk, and greater intake of fruits, vegetables, and whole grains [3]. - The Ministry will also create food maps for dairy and beef to integrate agricultural product consumption with cultural and tourism activities [3]. Group 3: Food Industry Upgrading - The Ministry of Industry and Information Technology emphasizes the need to establish a diversified food supply system and enhance the quality of the food industry to drive agricultural product consumption [4]. - The application of biotechnology in the food industry is being promoted to expand agricultural development, including the optimization of production processes for various food products [5]. - The Ministry is also focusing on developing local specialty food industries and promoting deep processing of food products to enhance agricultural product consumption quality [6].

方盛制药董秘：尊敬的投资者，您好!"创新生物技术中心"和"合成生物技术平台"是公司从"创仿结合、创仿平衡"（创新药与仿制药的平衡发展）的发展大战略出发，以公司控股子公司广东暨大 投资者：根据2024年年报，贵司的创新研究院新增加了"创新生物技术中心"和"合生生物技术平台"，请问这两个研究中心（平台）主要研究领域或方向是什么？能详细描述一下吗？ 方盛制药董秘：尊敬的投资者，您好!"创新生物技术中心"和"合成生物技术平台"是公司从"创仿结合、创仿平衡"（创新药与仿制药的平衡发展）的发展大战略出发，以公司控股子公司广东暨大 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 投资者：请问贵公司子公司广东暨大基因药物工程研究中心有限公司，发展的情况如何？ 证券之星消息，方盛制药(603998)07月29日在投资者关系平台上答复投资者关心的问题。 ...

Core Insights - National strategic investment platform Guotou Juli has completed a strategic investment of 450 million yuan in leading synthetic biology company Yikole Biotechnology [1] - Yikole's core competitiveness lies in its platform-based technology system, effectively overcoming the core bottleneck of "engineering transformation" in biological manufacturing [1] - The company has successfully achieved seamless scaling from "gram-level research" to "thousand-ton-level production" through its complete technology path and eight innovative technology platforms [1] Industry Positioning - Yikole is set to be the first in China to achieve market approval for high-value functional raw materials such as human milk oligosaccharides (HMOs), steviol glycosides, and nest acid from 2023 to 2025, gaining a first-mover advantage [2] - The company has established over 20 mature product lines in the fields of biomedicine, green agriculture, and life health [2] - Yikole has formed joint ventures with industry leaders, such as "Hongmo Bio" with Mengniu Group for HMOs commercialization and "Yikotang" with Jinhwa Industrial for health sweetener operations [2] Strategic Collaboration - Guotou Juli's investment aligns with the national strategy to accelerate the development of biological manufacturing and create new productive forces [3] - The collaboration will focus on innovative platform construction and cutting-edge technology application research [3] - Both parties will prioritize advancing biosynthesis technology using carbon compounds like carbon dioxide, carbon monoxide, and methanol, supporting the sustainable development strategy of "not competing with food for land or grain" [3]

Core Viewpoint - Green Biological Technology Co., Ltd. (hereinafter referred to as Green Biological) is making another attempt to go public (IPO) after two previous unsuccessful attempts, amidst a renewed wave of IPOs in the cosmetics raw material sector [1][2][5]. Company Overview - Green Biological was established in December 1999, focusing on the research, production, and sales of bio-based and fully synthetic fragrances. Its product lines include turpentine, cedarwood oil, and various synthetic fragrances [2][5]. - The company is one of the largest suppliers of methyl cedryl ketone in China, with significant usage in household and high-end perfume products [2][5]. - The founder, Lu Wencong, holds 27.11% of the company's shares, and his daughter holds an additional 9%, making them the actual controllers of the company [6][7]. IPO Attempts - Green Biological's first IPO attempt began in 2018, but it was halted in early 2021 due to issues related to information disclosure and a significant expected drop in net profit [5][9]. - The second attempt in June 2023 also ended in withdrawal due to similar concerns raised by the Shenzhen Stock Exchange regarding environmental issues and innovation capabilities [5][9]. Financial Performance - The company has shown strong revenue growth, with revenues of 594 million, 631 million, and 735 million yuan from 2021 to 2023, representing growth rates of 6.23%, 16.48%, and a compound annual growth rate of 10.92% [9][10]. - Net profits for the same period were 201.7 million yuan, with growth rates of 65.85% and 32.35% in 2022 and 2023, respectively, leading to a compound growth rate of 48.43% [9][10]. - As of the end of 2023, total assets reached 1.433 billion yuan, with a net profit of 92.92 million yuan and a return on equity of 20.65% [10][11]. Market Context - The cosmetics raw material market in China is projected to grow from 1147.80 billion yuan in 2019 to 1603.90 billion yuan by 2024, with a compound annual growth rate of 6.9% [14]. - The recent surge in IPOs among raw material suppliers is attributed to the booming cosmetics industry and favorable regulatory changes, including the establishment of the Beijing Stock Exchange and reforms in the Sci-Tech Innovation Board [15][16][17]. - Green Biological's export revenue has been significant, accounting for over 84% of its main business from 2021 to 2023, with major clients including Procter & Gamble and other international raw material suppliers [11][12].

Group 1 - The actual controller, chairman, and CEO of Juran Smart Home, Wang Linpeng, passed away on July 27, 2025, at home, and the company has made arrangements for daily operations to be managed by the executive team [2][4] - Wang Linpeng was regarded as a benchmark figure in the home furnishing industry, having over 25 years of experience in the field [4] Group 2 - The Songshan Shaolin Scenic Area announced that due to system upgrades, the original ticket purchasing channels will remain unchanged, and from July 31, 2025, the area will implement online reservation for ticket purchases [6] - The scenic area will suspend offline ticket sales for full-price tickets and for visitors under 18 years old, while retaining a small number of service windows for those eligible for exemption policies [6] Group 3 - ByteDance refuted claims that it arbitrarily canceled stock options for a former employee, stating that the cancellation was due to the employee violating company integrity management policies [7] - The former employee was found to have committed fraud, leading to significant economic losses for the company, and was taken into criminal custody by the police [7] Group 4 - Alibaba's Tongyi Qianwen API has reached a market share of 10.4%, surpassing OpenAI's 4.7%, ranking fourth globally in API call volume [10][11] - The total API call volume for Tongyi Qianwen exceeded 200 billion tokens in the past week [11] Group 5 - Tata Consultancy Services (TCS) announced plans to lay off approximately 12,000 employees, representing about 2% of its global workforce, due to declining industry demand [22] - The layoffs will primarily affect mid to senior-level employees and are aimed at entering new markets and expanding AI applications [22] Group 6 - Cheetah Mobile announced it will acquire over 80% of UFACTORY, a lightweight robotic arm supplier, for approximately 99.46 million yuan [23] - The acquisition has been approved by Cheetah Mobile's board and is expected to be completed in the third quarter of 2025 [23] Group 7 - The National Childcare Subsidy Program will provide annual subsidies of 3,600 yuan per child for infants under three years old starting January 1, 2025 [34] - The subsidy will be calculated based on the number of months eligible children are under three years old [34] Group 8 - The global pure semiconductor foundry revenue is projected to reach $165 billion in 2025, reflecting a 17% year-on-year growth [35] - This growth is part of a compound annual growth rate of 12% from 2021 to 2025 [35]

Core Viewpoint - The article emphasizes the significance of high-value compounds, such as amino acids and pharmaceutical intermediates, in the field of biomanufacturing, highlighting China's role as a major producer supporting global industry development [1]. Group 1: Biomanufacturing and Synthetic Biology - High-value compounds are crucial in biomanufacturing, with China being a leading producer in this sector [1]. - A major bottleneck in synthetic biology is the insufficient availability of biological components, which can be addressed through breakthroughs in enzyme design and gene editing technologies [1]. - The research team led by Professor Feng Yan from Shanghai Jiao Tong University focuses on developing efficient biocatalysts and new synthetic pathways for artificial compounds, surpassing natural evolution [1][3]. Group 2: Research Innovations - The research team utilizes second-generation sequencing for functional analysis of large mutation libraries, enabling rapid identification of important protein scenarios [1]. - The team has developed methods to create new proteins with over 50% sequence variation, which can be applied in the production of industrial enzymes [1]. Group 3: Upcoming Conference - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI and biomanufacturing, as well as opportunities in green chemistry, new materials, future food, and agriculture [6]. - The conference will feature various activities, including a macro forum on biomanufacturing, youth forums, and discussions on the 2025 Blue Book for AI-enabled biomanufacturing innovation [6][7].

Core Viewpoint - The article discusses the advancements in synthetic biology, particularly focusing on optimizing yeast metabolism for carbon conservation and fixation, which is crucial for reducing CO2 emissions and achieving sustainable chemical production [3][4][5]. Summary by Sections 1. Introduction to Carbon Emissions and Synthetic Biology - The increasing use of fossil resources is leading to higher CO2 emissions, raising global concerns about climate change and the urgent need for alternative solutions to achieve carbon neutrality [4]. - Synthetic biology enables the use of inexpensive substrates, such as lignocellulose, for chemical production, thereby reducing reliance on fossil resources [4]. 2. Yeast as a Platform for Biomanufacturing - Yeast is highlighted as a robust microbial chassis for industrial biomanufacturing, capable of producing various compounds like terpenes and fatty acids [5]. - The complexity of yeast metabolism often results in unavoidable CO2 release during chemical synthesis, primarily through glycolysis, pentose phosphate pathway, and tricarboxylic acid cycle [5][6]. 3. Carbon Conservation Systems in Yeast - The article reviews recent advancements in constructing carbon conservation and fixation systems in yeast, focusing on avoiding unnecessary decarboxylation reactions to reduce carbon loss [6][8]. - Strategies include enhancing natural carboxylation reactions to promote carbon conservation, with specific examples of engineered yeast strains achieving significant improvements in product yields [8][11]. 4. Engineering Strategies and Results - Various engineering strategies are discussed, such as the non-oxidative glycolysis (NOG) pathway, which has been successfully implemented in yeast to improve carbon efficiency and product yields [10][11]. - Specific results include a 25% increase in β-farnesene yield and an 80% increase in β-carotene production through metabolic engineering [11][12]. 5. Future Directions in Low-Carbon Yeast Cell Factories - The future of biomanufacturing involves constructing low-carbon yeast cell factories that can recycle CO2 released during production and potentially utilize CO2 directly as a substrate for product synthesis [19][20]. - The article outlines the integration of carbon fixation pathways, such as the Calvin cycle and reductive glycine pathways, into yeast to enhance CO2 utilization [19][21]. 6. Conclusion - The advancements in synthetic biology and metabolic engineering present promising opportunities for developing sustainable biomanufacturing processes that significantly reduce carbon emissions and enhance product yields [3][4][5].

7月25日，记者从中国科学院深圳先进技术研究院获悉，该院定量合成生物学全国重点实验室钟超 团队与上海交通大学医学院附属瑞金医院烧伤整形科刘琰团队开展联合攻关，成功研发出一款基于生物 纤维素的新型止血敷料T-BC，为烧伤及复杂创伤治疗提供了全新的材料解决策略。相关研究成果发表 在《先进材料》上。 临床烧伤清创术中的出血控制一直存在挑战。传统电凝止血虽有效，但存在热损伤周围组织的风险 且操作效率低；而常用止血剂则普遍存在换药时易引发再出血、贴附性差和机械强度不足等问题。针对 这些痛点，研究团队创造性地采用合成生物学技术，将重组人源凝血酶通过特异的纤维素与结构域精准 结合，并将其锚定在生物纤维素基体上，构建出兼具止血与促愈合功能的一体化敷料T-BC。该敷料通 过促进新血管形成、调控炎症反应和重建皮肤组织结构三重协同作用，在分子层面实现了对伤口修复过 程的多方位调控，从而显著加速愈合进程。 在大鼠肝脏切口模型中，该敷料能在1分钟内实现快速止血。在模拟深Ⅱ度烧伤创面的大鼠实验 中，使用T-BC进行治疗的实验组，5天后伤口愈合率较对照组提高了约40%。 此外，该研究采用生物分子自组装技术，仅需通过温和的蛋白溶液浸泡即可实 ...